

Date: 20<sup>th</sup> March, 2026

**BSE Limited**

P. J. Towers, Dalal Street, Fort,  
Complex, Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla  
Bandra (East), Mumbai - 400 051  
NSE Symbol: PPLPHARMA

**Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India  
(Listing Obligations and Disclosure Requirements) Regulations, 2015  
(‘SEBI Listing Regulations’) – ESG Ratings**

Dear Sir / Madam,

With reference to the captioned subject, please note that as per the information received by the Company on March 20, 2026, SES ESG Research Pvt. Ltd (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘**68.5**’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year.

The link for the rating as published is also available on the website of SES ESG - [SES ESG RELEASES ESG RATING FOR PIRAMAL PHARMA LTD](#)

Please note that the Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company.

This intimation is also being uploaded on the website of the Company at <https://www.piramalpharma.com/>.

Kindly treat this intimation for your information and record.

Thanking you.

Yours truly,

**For Piramal Pharma Limited**

**Pratibha Mishra**  
**Interim Company Secretary**

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India  
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

[piramalpharma.com](http://piramalpharma.com)